Linda has over 20 years of sales and business development experience in the biopharmaceutical industry in San Francisco, Boston, San Diego, and Washington, D.C.
Prior to starting 23andMe, she developed translational research collaborations with academic and pharmaceutical partners for Affymetrix and Perlegen Sciences. Linda also spent time at Spotfire helping scientists understand the power of data visualization and at Applied Biosystems during the early days of the human genome project. The advent of high density genome-wide scanning technologies brought huge potential for significant discoveries. However, the lack of sufficient funding to enable adequate studies prompted Linda to think of a new research model. These ideas led to the formation of 23andMe.
Her primary interest is the acceleration of personalized medicine, using genetic profiles to target the right drug to the right person at the correct dose.
Linda graduated from Augustana College with a B.A. in biology.
Attendance at the conference is by invitation only. DLD is produced by Hubert Burda Media.
Post a comment